XR-NTX 380 mg, intramuscular injection — Competitive Intelligence Brief

XR-NTX 380 mg, intramuscular injection (XR-NTX 380 mg, intramuscular injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor antagonist. Area: Psychiatry / Addiction Medicine.

marketed Opioid receptor antagonist Mu opioid receptor (primary); delta and kappa opioid receptors Psychiatry / Addiction Medicine Small molecule

Target snapshot

XR-NTX 380 mg, intramuscular injection (XR-NTX 380 mg, intramuscular injection) — University of Pennsylvania. XR-NTX 380 mg is an extended-release formulation of naltrexone that blocks opioid receptors to prevent opioid use and reduce cravings in opioid use disorder.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
XR-NTX 380 mg, intramuscular injection TARGET	XR-NTX 380 mg, intramuscular injection	University of Pennsylvania	marketed	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
MOVANTIK™ (naloxegol)	MOVANTIK™ (naloxegol)	Massachusetts General Hospital	marketed	Peripheral opioid receptor antagonist	Mu-opioid receptor (peripheral)
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)
Naltrexone Oral Product	Naltrexone Oral Product	Texas Tech University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
naltrexone (Revia)	naltrexone (Revia)	University of North Carolina, Chapel Hill	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
Naltrexone Tablet and Placebo Patch	Naltrexone Tablet and Placebo Patch	The Scripps Research Institute	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
long-lasting injectable naltrexone	long-lasting injectable naltrexone	State University of New York - Upstate Medical University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor antagonist class)

1. Albert Einstein Healthcare Network · 1 drug in this class
2. Cephalon · 1 drug in this class
3. Leiden University Medical Center · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. Paion UK Ltd. · 1 drug in this class
6. Pocket Naloxone Corp · 1 drug in this class
7. State University of New York - Upstate Medical University · 1 drug in this class
8. Texas Tech University · 1 drug in this class
9. The Scripps Research Institute · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class